Treatment for hepatitis delta
搜索文档
Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early (NASDAQ:VIR)
Seeking Alpha· 2025-11-06 02:42
技术访问问题 - 为确保未来正常访问 需在浏览器中启用Javascript和cookies [1] - 启用广告拦截器可能导致访问被阻止 需禁用广告拦截器并刷新页面 [1]
